Role of phospholipase A2 activation and calcium in CYP2E1-dependent toxicity in HepG2 cells.
Previous studies suggested a role for calcium in CYP2E1-dependent toxicity. The possible role of phospholipase A2 (PLA2) activation in this toxicity was investigated. HepG2 cells that overexpress CYP2E1 (E47 cells) exposed to arachidonic acid (AA) +Fe-NTA showed higher toxicity than control HepG2 cells not expressing CYP2E1 (C34 cells). This toxicity was inhibited by the PLA2 inhibitors aristolochic acid, quinacrine, and PTK. PLA2 activity assessed by release of preloaded [3H]AA after treatment with AA+Fe was higher in the CYP2E1 expressing HepG2 cells. This [3H]AA release was inhibited by PLA2 inhibitors, alpha-tocopherol, and by depleting Ca2+ from the cells (intracellular + extracellular sources), but not by removal of extracellular calcium alone. Toxicity was preceded by an increase in intracellular calcium caused by influx from the extracellular space, and this was prevented by PLA2 inhibitors. PLA2 inhibitors also blocked mitochondrial damage in the CYP2E1-expressing HepG2 cells exposed to AA+Fe. Ca2+ depletion and removal of extracellular calcium inhibited toxicity at early time periods, although a delayed toxicity was evident at later times in Ca2+-free medium. This later toxicity was also inhibited by PLA2 inhibitors. Analogous to PLA2 activity, Ca2+ depletion but not removal of extracellular calcium alone prevented the activation of calpain activity by AA+Fe. These results suggest that release of stored calcium by AA+Fe, induced by lipid peroxidation, can initially activate calpain and PLA2 activity, that PLA2 activation is critical for a subsequent increased influx of extracellular Ca2+, and that the combination of increased PLA2 and calpain activity, increased calcium and oxidative stress cause mitochondrial damage, that ultimately produces the rapid toxicity of AA+Fe in CYP2E1-expressing HepG2 cells.
Caro
Andres A
AA
Department of Pharmacology and Biological Chemistry, Mount Sinai School of Medicine, New York, New York 10029, USA.
Cederbaum
Arthur I
AI
D016718:Arachidonic Acid / Q000494:pharmacology; D034341:Aristolochic Acids / Q000494:pharmacology; D002118:Calcium / Q000378:metabolism; D002154:Calpain / Q000378:metabolism; D002470:Cell Survival; D019392:Cytochrome P-450 CYP2E1 / Q000737:chemistry* / Q000378:metabolism*; D004305:Dose-Response Relationship, Drug; D004789:Enzyme Activation; D004791:Enzyme Inhibitors / Q000494:pharmacology; D005434:Flow Cytometry; D006801:Humans; D007425:Intracellular Membranes / Q000378:metabolism; D015227:Lipid Peroxidation; D008564:Membrane Potentials; D008928:Mitochondria / Q000378:metabolism; D008954:Models, Biological; D018384:Oxidative Stress; D010741:Phospholipases A / Q000378:metabolism*; D054467:Phospholipases A2; D011505:Protein-Tyrosine Kinases / Q000378:metabolism; D011796:Quinacrine / Q000494:pharmacology; D017392:Thiobarbituric Acid Reactive Substances; D013997:Time Factors; D014407:Tumor Cells, Cultured; D024502:alpha-Tocopherol / Q000494:pharmacology
D034341:Aristolochic Acids; D004791:Enzyme Inhibitors; D017392:Thiobarbituric Acid Reactive Substances; D016718:Arachidonic Acid; C000228:aristolochic acid I; D019392:Cytochrome P-450 CYP2E1; D011505:Protein-Tyrosine Kinases; D010741:Phospholipases A; D054467:Phospholipases A2; D002154:Calpain; D011796:Quinacrine; D024502:alpha-Tocopherol; D002118:Calcium